Everest Medicines Announces Acceptance of VELSIPITY New Drug Application in Hong Kong Dec 02, 2024 10:34 HKT |  |
|
雲頂新耀宣佈中國香港衛生署正式受理伊曲莫德(VELSIPITY(R)) Dec 02, 2024 10:30 HKT |  |
|
云顶新耀宣布中国香港卫生署正式受理伊曲莫德(VELSIPITY(R)) Dec 02, 2024 10:25 HKT |  |
|
Hua Medicine Announces Successful U.S. Phase I Results on Its 2nd Generation GKA Candidate Nov 30, 2024 21:08 HKT |  |
|
華領醫藥宣佈成功完成在美國開展的第二代葡萄糖激酶激活劑I期臨床研究 Nov 30, 2024 20:56 HKT |  |
|
华领医药宣布成功完成在美国开展的第二代葡萄糖激酶激活剂I期临床研究 Nov 30, 2024 20:46 HKT |  |
|
Hua Medicine Announces Successful H.K. SENSITIZE Study Results at the CBIIC Nov 30, 2024 20:34 HKT |  |
|
華領醫藥宣佈成功完成在中國香港開展的SENSITIZE研究 Nov 30, 2024 20:11 HKT |  |
|
华领医药宣布成功完成在中国香港开展的SENSITIZE研究 Nov 30, 2024 19:58 HKT |  |
|
NEFECON(R) Included in National Reimbursement Drug List (NRDL) Nov 29, 2024 10:48 HKT | |
|
耐賦康(R)納入新版國家醫保藥品目錄 Nov 29, 2024 10:45 HKT | |
|
耐赋康(R)纳入新版国家医保药品目录 Nov 29, 2024 10:42 HKT | |
|
「依拉環素臨床應用綜合評價項目」終期報告發佈 Nov 26, 2024 11:11 HKT | |
|
'依拉环素临床应用综合评价项目'终期报告发布 Nov 26, 2024 11:04 HKT | |
|
Everest Medicines Announces NEFECON(R)'s Full Approval in South Korea Nov 19, 2024 17:37 HKT | |
|
雲頂新耀宣佈耐賦康(R)在韓國獲批 商業化進程再創里程碑 Nov 19, 2024 17:28 HKT | |
|
云顶新耀宣布耐赋康(R)在韩国获批 商业化进程再创里程碑 Nov 19, 2024 17:10 HKT | |
|
雲頂新耀宣佈耐賦康(R)Ⅲ期試驗開放標籤第二療程擴展研究積極結果 Nov 11, 2024 12:23 HKT | |
|
云顶新耀宣布耐赋康(R)Ⅲ期试验开放标签第二疗程扩展研究积极结果 Nov 11, 2024 12:15 HKT | |
|
Everest Medicines Announces the Launch of VELSIPITY(R) in the Guangdong-Hong Kong-Macau Greater Bay Area Oct 25, 2024 11:28 HKT | |
|
<< Previous
Next >>
|